111 (NASDAQ:YI) & Veeva Systems (NYSE:VEEV) Head to Head Comparison

Veeva Systems (NYSE:VEEV) and 111 (NASDAQ:YI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

88.2% of Veeva Systems shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 10.3% of Veeva Systems shares are owned by company insiders. Comparatively, 43.9% of 111 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Veeva Systems has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares Veeva Systems and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veeva Systems	27.93%	13.68%	11.27%
111	-0.52%	N/A	-2.70%

Earnings & Valuation

This table compares Veeva Systems and 111″s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veeva Systems	$2.75 billion	13.14	$714.14 million	$5.14	42.70
111	$13.58 billion	0.00	-$1.42 million	($0.84)	-3.29

Veeva Systems has higher earnings, but lower revenue than 111. 111 is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Veeva Systems and 111, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veeva Systems	2	6	18	0	2.62
111	1	0	0	0	1.00

Veeva Systems currently has a consensus price target of $307.42, suggesting a potential upside of 40.07%. Given Veeva Systems’ stronger consensus rating and higher possible upside, analysts clearly believe Veeva Systems is more favorable than 111.

Summary

Veeva Systems beats 111 on 12 of the 14 factors compared between the two stocks.

About Veeva Systems

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.